NCT07198555招募中1 期
A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-A101 in the Treatment of Knee Osteoarthritis .
Belief BioMed (Beijing) Co., Ltd2 个研究点 分布在 1 个国家目标入组 81 人开始时间: 2025年10月9日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 81
- 试验地点
- 2
- 主要终点
- Incidence of dose limiting toxicity (DLT) events
研究概览
简要总结
The purpose of the study is to evaluate the safety, tolerability, and efficacy of BBM-A101 to treat participants with knee osteoarthritis.
详细描述
This study is divided into two phases: Phase Ia and Phase Ib . Phase Ia is a randomized, single-blind study . Phase Ib is a randomized, double blind, parallel assignment study.
BBM-A101 is an AAVbased gene therapy that delivers a therapeutic gene cassette into knee for the treatment of knee osteoarthritis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
The masking subjects in the Ia phase is participant , but the phase Ib study is double-blind
入排标准
- 年龄范围
- 40 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with moderate knee osteoarthritis .
- •The knee joint was evaluated as having Kellgren-Lawrence grade 2 or
- •The Body Mass Index (BMI) ranges from 18.0 to 35.0 kg/m2 (including the boundary values).
- •Lower titers of antibodies binding to the BBM-A101 capsid in the blood.
- •Participants who had received adequate treatment with conventional medications previously, experienced recurrence or aggravation of target knee arthritis after discontinuation of medication, and still had moderate pain; during the screening period, the WOMAC pain score of the target knee was ≥ 8 .
- •From the time of screening to 52 weeks after dosing , the participants had no intention of having children and voluntarily took effective contraceptive measures, and there were no plans for sperm donation or ova donation.
- •Voluntarily sign the informed consent form and be able to complete the research as required by the clinical trial protocol.
排除标准
- •There is a possibility of secondary knee osteoarthritis, or the knee joint symptoms may not be caused by knee osteoarthritis, or there may be other medical histories of diseases that other researchers believe could potentially lead to knee osteoarthritic inflammation.
- •History of lumbar dischernaiation, accompanied by lower limb nerve symptoms that may affect the assessment of the study.
- •Participants who are unable or unwilling to undergo MRI examination, or who have contraindications to MRI.
- •Participants who are unable or unwilling to undergo joint fluid extraction.
- •During the screening period and before dosing, there were clinically significant abnormal values in the laboratory tests, and the researchers believed that these might pose risks to the participants in the clinical trial.
- •Those with positive results for hepatitis B virus surface antigen or hepatitis B virus deoxyribonucleic acid or hepatitis C virus ribonucleic acid test or human immunodeficiency virus antibody or Treponema pallidum antibody.
- •Currently undergoing treatment for hepatitis B and hepatitis C.
- •Participants who had persistent chronic or active infections within the previous 4 weeks were selected.
- •Participants who had coagulation disorders (such as hemophilia) or existing medical conditions that require anticoagulation therapy and make knee joint injection impossible.
- •Having or having had cancer or malignant tumors
- •Having received genetic therapy or stem cell therapy before screening or having plans for genetic therapy or stem cell therapy during the study period.
- •Any history of vaccination within 30 days prior to dosing or any vaccination schedule within 30 days after dosing.
- •Screening will be conducted on female participants who are pregnant or breastfeeding or whose HCG test result is positive; or who have plans to get pregnant within the next 52 w.
- •History of alcohol addiction or drug dependence, or inability to limit alcohol consumption during the research process.
- •Participants had any mental disorders that might affect the assessment of the study.
- •Having other conditions that the investigator consider unsuitable for participation in the study.
研究组 & 干预措施
Arm of Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Arm of BBM-A101
Experimental
干预措施: BBM-A101 (Drug)
结局指标
主要结局
Incidence of dose limiting toxicity (DLT) events
时间窗: within 4 weeks
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
时间窗: within 52 weeks
To evaluate the safety of BBM-A101 by AEs and SAEs.
次要结局
- The protein levels of gene expression products in blood and joint fluid(within5 years)
- The shedding of recombinant adeno-associated virus (rAAV) vectors in peripheral blood, joint fluid, urine, feces, saliva, and semen(within 5 years)
- The change in the joint space width as detected by X-ray of the knee joint compared to the baseline(within 5 years)
- The changes in the titers of AAV capsid-binding antibodies in the blood and joint fluid compared to the baseline level(within 5 years)
- The changes in the titers of antibodies binding to the expressed products in the blood and joint fluid compared to the baseline level(within 5 years)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.NCT06927466Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.33
招募中
1 期
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.DMDNCT07058662Belief BioMed (Beijing) Co., Ltd9
已完成
1 期
Safety and Tolerability Study of BMS-986177 in Healthy SubjectsThrombosisNCT02608970Bristol-Myers Squibb104
招募中
1 期
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsSmall Cell Lung CancerBreast CancerLung CancerOvarian CancerCervical CancerEsophageal CancerNCT05983432SystImmune Inc.470
招募中
早期 1 期
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD)NCT06641895Shanghai Jiao Tong University School of Medicine6